search

Active clinical trials for "Primary Immunodeficiency Diseases"

Results 1-10 of 177

Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human...

Primary Immune Deficiency

Prospective, open-label, single-arm, multicentre Phase 3 study to evaluate the pharmacokinetics, efficacy, tolerability, and safety of subcutaneous human immunoglobulin (Newnorm) in patients with primary immunodeficiency diseases

Recruiting32 enrollment criteria

Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts...

Viral InfectionHematopoietic Stem Cell Transplantation (HSCT)1 more

This is a Phase I dose-escalation study to evaluate the safety of norovirus -specific T-cell (NST) therapy for chronic norovirus infection in participants following hematopoietic stem cell transplantation (HSCT) or with primary immunodeficiency disorders (PID) who have not undergone HSCT.

Recruiting57 enrollment criteria

Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs)

Viral InfectionPrimary Immune Deficiency Disorder

BK cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be safe and effective in decreasing specific viral load in children, adolescents and young adults (CAYA) with refractory BK infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) or with primary immunodeficiencies (PID).

Recruiting19 enrollment criteria

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies

SCIDOmenn's Syndrome12 more

This is a standard of care treatment guideline for allogeneic hematopoetic stem cell transplant (HSCT) in patients with primary immune deficiencies.

Recruiting31 enrollment criteria

Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome

Activated PI3K-delta SyndromeImmunodeficiency Primary

The purpose of this proposed research is to evaluate the efficacy and safety of the rapamycin therapy in patients with activated phosphoinositide 3-kinase δ syndrome (APDS).

Recruiting5 enrollment criteria

Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection

AdenovirusPrimary Immune Deficiency Disorder

Related donor Adenovirus (ADV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered intravenously in in children, adolescents and young adults with refractory ADV infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. Funding Source: FDA OOPD

Recruiting17 enrollment criteria

Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients...

Primary Immunodeficiency Disease

The purpose of this study is to assess efficacy, safety and pharmacokinetics of Kedrion Immunoglobulin 10% (KIg10) in pediatric patients with Primary Immunodeficiency Disease (PID).

Recruiting45 enrollment criteria

A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases

Epstein-Barr Virus (EBV)-Associated DiseasesEBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD)9 more

The purpose of this study is to assess the efficacy and safety of tabelecleucel in participants with Epstein-Barr virus (EBV) associated diseases.

Recruiting39 enrollment criteria

Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency...

Primary Immune Deficiency

The purpose of this study is to evaluate the pharmacokinetics and safety of Immune Globulin Intravenous (Human) GC5107 in pediatric subjects with Primary Humoral Immunodeficiency (PHID).

Recruiting11 enrollment criteria

Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT

Primary Immunodeficiency (PID)Congenital Bone Marrow Failure Syndromes4 more

The objective of this study is to evaluate the efficacy of using a reduced-intensity condition (RIC) regimen with umbilical cord blood transplant (UCBT), double cord UCBT, matched unrelated donor (MUD) bone marrow transplant (BMT) or peripheral blood stem cell transplant (PBSCT) in patients with non-malignant disorders that are amenable to treatment with hematopoietic stem cell transplant (HSCT). After transplant, subjects will be followed for late effects and for ongoing graft success.

Recruiting64 enrollment criteria
12...18

Need Help? Contact our team!


We'll reach out to this number within 24 hrs